| 2025-05-05 | -0.34 % |
|
| 2025-05-02 | +2.65 % |
|
| 2025-05-01 | -1.46 % |
|
| 2025-04-30 | +5.25 % |
|
| 2025-04-29 | -6.87 % |
|
| 2025-04-25 | +0.48 % |
- Regeneron Pharmaceuticals (REGN) stock rose 0.48% following an upgrade by Canaccord Genuity from a hold to a strong-buy rating, alongside positive sentiments from several other analysts regarding its earnings performance and future prospects.
- Regeneron Pharmaceuticals (REGN) stock increased by 0.48% following a mixed assessment from analysts, with one firm reducing its price target while others maintained or upgraded their ratings, reflecting ongoing confidence in the company's potential despite the target changes.
The stock rose likely due to strong earnings performance that exceeded analysts' expectations and a generally positive outlook from multiple research firms, suggesting potential significant upside.
- The article discusses the recent performance of Regeneron Pharmaceuticals (REGN) stock, which saw a 0.48% increase, while primarily focusing on bluebird bio, Inc. (BLUE), its stock recommendations, and analysts' ratings.
The increase in Regeneron Pharmaceuticals' stock could be attributed to positive market sentiment, potentially stemming from recent upgrades in the biotechnology sector or investor interest in its gene therapy developments.
- Regeneron Pharmaceuticals (REGN) stock rose by 0.48% recently, likely due to its significant investment in Intellia Therapeutics and broader involvement from institutional investors, which may indicate confidence in the company's growth and potential.
- Regeneron Pharmaceuticals (REGN) stock rose by 0.48% after Cantor Fitzgerald initiated coverage with an "overweight" rating and a $695.00 price target, contributing to a positive sentiment among investors in light of favorable earnings estimates for FY2025.
- Regeneron Pharmaceuticals' stock rose 0.48% following Cantor Fitzgerald's bullish FY2025 earnings per share estimate of $26.38 and an "Overweight" rating with a target price of $695, boosting investor confidence despite other analysts lowering their price targets.
|
| 2025-04-23 | +0.4 % |
|
| 2025-04-22 | +4.27 % |
|
| 2025-04-21 | -0.3 % |
|
| 2025-04-16 | -1.55 % |
|
| 2025-04-15 | -2.3 % |
|
| 2025-04-08 | -2.79 % |
|
| 2025-04-04 | -6.09 % |
|
| 2025-04-02 | +1.39 % |
|
| 2025-04-01 | -2.72 % |
|
| 2025-03-28 | +0.24 % |
|
| 2025-03-26 | +0.95 % |
|
| 2025-03-25 | -4.06 % |
|
| 2025-03-20 | -1.45 % |
|
| 2025-03-19 | +1.11 % |
|
| 2025-03-18 | -1.98 % |
|
| 2025-03-17 | +1.73 % |
|
| 2025-03-14 | -2.02 % |
|
| 2025-03-12 | -3.99 % |
|
| 2025-03-11 | -3.58 % |
|
| 2025-03-07 | +1.3 % |
|
| 2025-03-06 | +1.64 % |
|
| 2025-02-27 | -0.59 % |
|
| 2025-02-26 | -2.28 % |
|
| 2025-02-24 | +1.84 % |
|
| 2025-02-21 | +0.62 % |
|
| 2025-02-19 | +0.83 % |
|
| 2025-02-18 | +0.95 % |
|
| 2025-02-14 | -0.1 % |
|
| 2025-02-13 | +1.57 % |
|
| 2025-02-12 | -0.24 % |
|
| 2025-02-11 | -3.61 % |
|
| 2025-02-10 | -2.77 % |
|
| 2025-02-07 | -1.67 % |
|
| 2025-02-06 | +0.75 % |
|
| 2025-02-05 | +2.82 % |
|
| 2025-02-04 | +4.53 % |
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% following the company's strong fourth-quarter earnings report, which included a 2% year-over-year increase in adjusted EPS that exceeded expectations, sales growth of 10% beating consensus estimates, the announcement of a new quarterly cash dividend, and an authorization of an additional $3 billion for share repurchases.
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% following the company's positive financial results for Q4 and full year 2024, alongside the announcement of a new quarterly dividend program and increased share repurchase capacity, highlighting robust revenue growth and successful pipeline advancement in their R&D initiatives.
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% last night amid ongoing scrutiny over potential legal issues related to alleged misleading statements concerning their Eylea drug pricing and sales practices, which have led to DOJ investigations. The stock increase could be attributed to investor sentiment responding positively to the legal developments or market anticipation for company performance improvements following recent challenges.
- Regeneron Pharmaceuticals' stock rose following strong fourth-quarter sales and profit results that exceeded analysts' expectations, driven by heightened demand for its eczema treatment Dupixent, a dividend announcement, and an expansive share buyback program. The stock's increase can be attributed to better-than-expected financial performance, including additional revenue from Eylea and Libtayo, and strategic initiatives like the dividend and buyback that enhance shareholder value.
- Regeneron Pharmaceuticals (REGN) stock rose by 4.53% after the company exceeded fourth-quarter sales and profit expectations due to strong demand for its eczema treatment, Dupixent, while also introducing a dividend and stock buyback program.
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% following the company’s announcement of stronger-than-expected fourth-quarter earnings of $12.07 per share and $3.79 billion in sales, surpassing analyst expectations.
|
| 2025-02-03 | -0.91 % |
|
| 2025-01-31 | -1.48 % |
|
| 2025-01-29 | +0.14 % |
|
| 2025-01-28 | +0.24 % |
|
| 2025-01-27 | +1.32 % |
|
| 2025-01-24 | -2.71 % |
|
| 2025-01-22 | -1.13 % |
|
| 2025-01-21 | +0.91 % |
|
| 2025-01-17 | -1.68 % |
|
| 2025-01-16 | -1.45 % |
|
| 2025-01-15 | +1.82 % |
|
| 2025-01-14 | -3.63 % |
|
| 2025-01-13 | +2.87 % |
|
| 2025-01-10 | -5 % |
|
| 2025-01-08 | +0.45 % |
|
| 2025-01-07 | +1.96 % |
|
| 2024-12-19 | -0.89 % |
|
| 2024-12-06 | +1.32 % |
|
| 2024-12-04 | +0.63 % |
|
| 2024-12-03 | -1.68 % |
|
| 2024-11-27 | +0.24 % |
|
| 2024-11-21 | +0.15 % |
|
| 2024-11-19 | -2.28 % |
|
| 2024-11-18 | +0.69 % |
|
| 2024-11-15 | -3.28 % |
|
| 2024-11-14 | -2.71 % |
|
| 2024-11-11 | -0.33 % |
|
| 2024-11-08 | +0.48 % |
|
| 2024-11-06 | -1.54 % |
|
